General
Preferred name
CEFIXIME
Synonyms
CL-284635 ()
FK-027 ()
FR-17027 ()
Cefiximum ()
Cephoral ()
Cefspan ()
CEFIXIME ANHYDROUS ()
FR-17027 (trihydrate) ()
FK-027 (trihydrate) ()
CL-284635 (trihydrate) ()
Cefixime (trihydrate) ()
Cefixima, Cefiximum, Cephoral, Cefspan, FR-17027, FK-027, CL-284635 ()
Anhydrous cefixime ()
Citropen ()
Cefixima ()
FR 17027 ()
CL 284,635 ()
Suprax ()
Cefixime hydrate ()
CEFIXIME TRIHYDRATE ()
FK 027 ()
Oroken ()
P&D ID
PD009856
CAS
79350-37-1
125110-14-7
Tags
available
drug
covalent binder
Approved by
FDA
First approval
1989
Drug indication
Antibacterial
Bacterial infection
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Cefixime is a broad-spectrum, third-generation, orally active cephalosporin antibacterial. (GtoPdb)
Compound Sets
20
AdooQ Bioactive Compound Library
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NPC Screening Collection
Prestwick Chemical Library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
External IDs
49
Properties
(calculated by RDKit )
Molecular Weight
453.04
Hydrogen Bond Acceptors
10
Hydrogen Bond Donors
4
Rotatable Bonds
8
Ring Count
3
Aromatic Ring Count
1
cLogP
-0.54
TPSA
184.51
Fraction CSP3
0.25
Chiral centers
2.0
Largest ring
6.0
QED
0.23
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Pathway
Microbiology&virology
Anti-infection
Target
PBPs
antibiotic
Bacterial
Antibiotics,Antineoplastic and Immunosuppressive Antibiotics,Bacterial
Disease Area
infectious disease, otolaryngology, pulmonary
Indication
urinary tract infections, otitis, pharyngitis, tonsillitis, gonorrhea, bronchitis
MOA
bacterial cell wall synthesis inhibitor
Therapeutic Class
Antibiotics
Source data